drugset / Trial / NCT02607813
Phase I Study of LXH254 in Patients With Advanced Solid Tumors Haboring MAPK Pathway Alterations
Non-randomizedParallel-groupOpen-labelTreatment
Summary
A Phase I Study of LXH254 in Patients With Advanced Solid Tumors That Harbor MAPK Pathway Alterations.
Timeline
- Start
- 2016-01-18
- Primary completion
- 2022-02-18
- Completion
- 2022-02-19
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Naporafenib | Small molecule | — | Oral |
| Subject | Spartalizumab | Monoclonal antibody | — | — |